cystic fibrosis

The Cystic Fibrosis Foundation will award up to $11 million to Icagen to support a multi-year research-program aiming to develop new therapies for patients with cystic fibrosis (CF) caused by nonsense mutations, who may fail to respond to the current CFTR modulator therapies. The aim of the research is to…

When the Cystic Fibrosis Foundation (CFF) was established in 1955, most people with cystic fibrosis (CF) didn’t make it to their sixth birthday. Today, the average life expectancy of a CF patient is 47 years. To date, the U.S. Food and Drug Administration has approved 12 CF therapies. Three of…

Vertex Pharmaceuticals recently awarded $400,000 in scholarships for people living with cystic fibrosis (CF) and their family members, as part of its second “All in for CF” scholarship program. The program awarded 80 scholarships worth $5,000 each, to allow more people to pursue higher education in the…

AllianceRx Walgreens Prime announced that it has access to a series of limited-distribution drugs (LDDs) for its specialty patients, including the recently approved Symdeko (tezacaftor/ivacaftor and ivacaftor) for cystic fibrosis (CF). Other medications available include Austedo (deutetrabenazine) for Huntington’s disease, Fasenra (benralizumab) for severe asthma, and Hemlibra…

Vertex Pharmaceuticals is launching Phase 3 clinical trials to evaluate the safety and effectiveness of its investigational therapy, VX-445, in combination with VX-661 (tezacaftor) and Kalydeco (ivacaftor) for cystic fibrosis (CF). The AURORA program will consist of two randomized, double-blind Phase 3 trials — AURORA F/MF…

The Northeast Texas chapter of the Cystic Fibrosis Foundation (CFF) is holding its 2018 Dallas Wine Opener on Friday night, May 4, to raise money for cystic fibrosis research and improve the lives of patients and caregivers. The annual “cocktail attire” event is a gathering of more than…

Certain medications used to treat acid reflux are associated with an increased risk of hospitalization in cystic fibrosis (CF) patients, a study shows. Gastroesophageal reflux disease (GERD, aka acid reflux), which occurs when acid from the stomach rises into the esophagus causing heartburn, is more common in CF patients —…

It is now possible to identify genetic catalysts that accelerate the evolution of antibiotic resistance in bacteria, thanks to a team of researchers at University of Oxford, U.K. The findings could be used to design treatments to stop the development of antibiotic resistance. The data were published in the journal…

Galapagos is starting a clinical trial called FALCON to evaluate a new triple-combination therapy to treat cystic fibrosis patients. The combination treatment, using experimental therapies GLPG2451, GLPG2222, and GLPG2737, all developed by Galapagos, shows early potential in non-human studies for treating cystic fibrosis. In vitro assays have consistently…

Eloxx Pharmaceuticals announced plans to begin Phase 2 studies of ELX-02, its lead candidate to treat cystic fibrosis (CF) and cystinosis, having finished one round of Phase 1 safety and tolerability studies in healthy volunteers. This single, ascending dose study was conducted in a total of 60 people in Israel (NCT02807961)…